

MASTERCLASS IN DEMENTIA AND DELIRIUM

Masterclass Dementia and Delirium Program

This seminar will be delivered by a combination of a 6-week self-paced learning package followed by a live one-day seminar

Self-paced learning package

The self-paced learning package comprises approximately 3 hours of learning materials. The self-paced learning package materials must be completed prior to attending the live virtual seminar.

| Topic 1: Dementia | |
|--------------------------------------|---|
| Topics covered & presenters | Learning objectives |
| Pathophysiology | <ul style="list-style-type: none"> Outline the pathophysiology underlining common types of dementia Describe basic brain anatomy and how damage to different areas leads to specific cognitive symptoms Understand the risk factors for dementia and cognitive decline and what can be done to mitigate this risk Explain hypothesized pathophysiology for upcoming treatment options |
| Diagnosis and cognitive tests | <ul style="list-style-type: none"> Outline the steps and complexities involved in a dementia diagnosis Understand how brain imaging techniques aid a dementia diagnosis Interpret the results of commonly used cognitive tests and how clinicians may apply these results in practice |
| Available treatments | <ul style="list-style-type: none"> Overview the pharmacology of anticholinesterases and memantine Interpret the evidence for these therapies in the different types of dementia Discuss the limitations of these therapies and their role in practice |
| Future treatments | <ul style="list-style-type: none"> Interpret the evidence for anti-amyloid therapies for Alzheimer's Disease Evaluate the proposed benefits and limitations of anti-amyloid therapy and |

MASTERCLASS IN DEMENTIA AND DELIRIUM

| | |
|---|--|
| | their role in the management of dementia |
| BPSD in dementia | <ul style="list-style-type: none"> • Describe the different types of behaviours that may occur and identify which behaviours are appropriate for pharmacological management • Evaluate the evidence available for antipsychotic use in BPSD • Compare and contrast the different antipsychotics used for BPSD and identify appropriate therapy • Identify the risks involved in antipsychotic use and how antipsychotic stewardship may mitigate these risks |
| Topic 2: Delirium | |
| Topics covered & presenters | Learning objectives |
| Background | <ul style="list-style-type: none"> • Describe the common types of delirium presentations and their associated risks. • Identify the risk factors for delirium: modifiable and non-modifiable. • Overview the epidemiology of delirium. • Describe predisposing and precipitant risk factors for delirium. • Define the concept of the vulnerable brain. • Outline the systems integration failure hypothesis. |
| Diagnosis | <ul style="list-style-type: none"> • Describe the common tools used to detect delirium. • Describe the detection and evaluation of a patient with delirium: to touch on delirium in different settings, ICU/post-op/EOLC etc. |
| Management & Pharmacist role | <ul style="list-style-type: none"> • Outline the non-pharmacological interventions used to manage patients with delirium. • Describe the differences in pharmacological management based on |

MASTERCLASS IN DEMENTIA AND DELIRIUM

| | |
|--|--|
| | <p>delirium cause e.g. substance withdrawal, end of life.</p> <ul style="list-style-type: none">• Discuss how medications can precipitate delirium.• Describe common medications that can precipitate/compound delirium focusing on neurotransmitter pathways.• Outline the evaluation and management of delirium and the role of interprofessional team members in collaborating to provide well-coordinated care and enhance patient outcomes. |
| Behaviours of concern in delirium | <ul style="list-style-type: none">• Describe the different types of behaviours that may occur and identify which behaviours are appropriate for pharmacological management in delirium.• Evaluate the evidence available for antipsychotic use in delirium.• Compare and contrast the different antipsychotics used for behaviours of concern in delirium and identify appropriate therapy |

MASTERCLASS IN DEMENTIA AND DELIRIUM

Masterclass Dementia and Delirium Program

Live virtual seminar: Saturday 18 May 2024

All times listed are in AEST. The below may be subject to change

| Time AEST | Session |
|-------------------------|---|
| 0900 – 0910 | Welcome/introductions |
| 0910 – 0930 | Q&A from self-paced learning package |
| Part 1: Dementia | |
| 0930 – 1030 | Case Session 1 |
| 1030- 1040 | Morning tea break |
| 1040 – 1110 | Presentation: Complex BPSD |
| 1110 - 1140 | Case Session 1.2 |
| 1140 - 1210 | Expert Panel Discussion - Dementia |
| 1210 - 1240 | Lunch break |
| Part 2: Delirium | |
| 1240 – 1330 | Case Session 2 |
| 1330 - 1400 | Presentation: Managing behaviours of concern in delirium |
| 1400 – 1410 | Afternoon tea break |
| 1410 – 1500 | Case Session 3 |
| 1500 – 1530 | Expert Panel Discussion – Hypoactive and Hyperactive Delirium |
| 1530 – 1545 | Presentation: Polypharmacy Stewardship Roles |
| 1545 | Program wrap up & close |

Please note: presentation recordings from the live virtual seminar will not be available